Siemens Siemens.com Siemens diagnostics.com
Site Map / Site Index / Search
     
 
HOME
Hospitalization and Malnutrition
Improving Patient Management
JCAHO Guidelines
Nutritional Assessment Strategies
Reimbursement
Diagnostic Challenges
Nutrition Partnership Program
Strategies for Nutritional Assessment Protocols

The Role of Laboratory Testing

In recent years, plasma protein markers have been shown to be reliable indicators of nutritional status. The rationale for using protein markers is based on their importance as mediators of most physiological reactions and intercellular communications and on the general inability of the body to store either proteins or amino acids. Unfortunately, there is no single "magic bullet" marker that can be used all the time.

Ideal Plasma Protein Marker Characteristics for
Evaluating Nutritional Status

  • Short half-life (< 2 days) in the circulation
  • Rapid response to improved nutrient intake
  • Ability to reflect moderately decreased intake
  • Ability to accurately indicate current nutritional status
  • Ability to accurately reflect the degree of nutritional deficiency
  • Insensitivity to non-nutritional factors

Features of Selected Protein Markers

Marker
Advantages
Disadvantages
Albumin
  • Easy and inexpensive to measure
  • Covered by most reimbursement programs
  • Extremely long half-life (~20 days); insensitive to short-term changes
  • Insensitive to trauma- or stress-induced malnutrition (see section on the hypermetabolic state)
  • Affected by over-hydration and dehydration; Often given as part of therapy
  • Affected by non-nutritional factors (including liver and kidney disease)
Marker
Advantages
Disadvantages
Transferrin
  • Shorter half-life (~8 days) than albumin
  • Decreased level in severe malnutrition
  • Half-life still too long for ongoing assessment (evaluating response to therapy)
  • Strongly affected by iron deficiency (transferrin is an iron-support protein)
  • Sensitive to hormones and medications (particularly antibiotics affecting protein synthesis)
  • Affected by chronic infection or inflammatory disease
  • Strongly depressed in patients with liver disease; Depressed by infection/inflammation
Marker
Advantages
Disadvantages
Prealbumin (Transthryretin)
  • Short half-life (~2 days)
  • Excellent sensitivity to nutritional status
  • Very useful for classification/triage
  • High proportion of essential amino acids
  • Strongly depressed in patients with end-stage liver disease
  • Depressed by infection/inflammation
Marker
Advantages
Disadvantages
Retinol-Binding Protein (RBP)
  • Very short half-life (~10 hours)
  • Excellent sensitivity to nutritional status
  • Helps "fill in the gaps" when used with prealbumin
  • Strongly affected by kidney disease
  • Compromised by infection/inflammation
  • Very sensitive to cancer-induced cachexia

A. Michael Spiekerman, PhD Chief, Chemistry Scott and White Clinic
Full Professor of Pathology and Laboratory Medicine College of Medicine
Texas A&M University, Temple, Texas

 

Click to hear AudioThe Perils and Pitfalls of Albumin

Click to hear AudioThe Essential Benefits of Prealbumin

Click to hear Audio Retinol-Binding Protein: Responding Quickly to Nutritional Changes

Click to hear Audio Protein Markers Defining Entropy Points

 

 

 

 

The table below summarizes the half-life, normal ranges, and medical decision points for each of the principal plasma protein markers described above:

Specifics of Selected Protein Markers

Marker
Half-life
Normal Range
Medical Decision Point
Albumin
~20 days
3.5-5.5 g/dL 3.0 g/dL
Transferrin
~8 days
200-400 mg/dL 150 mg/dL
Prealbumin ~2 days 16-35 mg/dL 11 mg/dL
Retinol-Binding Protein
~10 hours 2.6-7.6 mg/dL 1.6 mg/dL



To see the potential benefits of an effective nutritional assessment program in your institution click here.

You must have the Flash 4.0 plug-in to view the interactive chart. To view it without the plug-in, please click here.

 

Visitors: Register Now!
Members: Update your
registration Information

E-mail this page to a friend

Rate This Page

Glossary / What's New!

© Siemens Healthcare Diagnostics Inc. 2007-2008  |  Corporate Information  |  Privacy Policy  |  Terms of Use